Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.

Latest From Sten Stovall

Kancera Targets COVID-19 With Fractalkine Inhibitor

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

Clinical Trials Companies

‘Follow The Money’: Sweden’s Calliditas Plans US Listing

Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.

Companies Financing

Oculis’s OCS-01 Sparkles Treating Front-Of-Eye Inflammation

Oculis’s eyedrop OCS-01 showed high efficacy treating post-cataract inflammation in front of the eye, adding to its effective use in back-of-the-eye conditions.

Clinical Trials Companies

High Efficacy Halts ViiV HIV Prevention Study Early

Prospects have improved for ViiV’s long-acting, injectable cabotegravir to be approved early for HIV prevention after a Phase III trial was stopped early due to efficacy.

Clinical Trials Companies

Sweden’s Affibody Inks Inmagene China R&D Pact

Swedish biotech Affibody hopes an R&D alliance with China-based Inmagene Biopharmaceuticals will speed development of its lead compound for auto-immune diseases.

Deals Immune Disorders

Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial

Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.    

Coronavirus COVID-19 Clinical Trials
See All
UsernamePublicRestriction

Register